Tenax Therapeutics, Inc. (TENX) 10-Year Financial Performance & Capital Metrics

TENX • • Industrial / General

HealthcareBiotechnologyMetabolic & Liver DiseasesNASH & Liver Diseases

AboutTenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.Show more

Revenue $0
EBITDA -$18M -113.7%
Net Income -$18M -128.3%
EPS (Diluted) -1.15 +96.3%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -35.17% +78.1%
ROIC -
Debt/Equity -
Interest Coverage -847.57 -146.7%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 96 (top 4%)

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Shares diluted 100.0% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-197.57%

EPS CAGR

10Y-

5Y-

3Y-

TTM92.92%

ROCE

10Y Avg-191.29%

5Y Avg-304.4%

3Y Avg-192.95%

Latest-38.95%

Peer Comparison

NASH & Liver Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
MAZEMaze Therapeutics, Inc.	1.92B	39.81	511.70		31.18%	-33.24%	3.91%	0.14
GNFTGenfit S.A.	313.52M	6.27	209	134.56%	-14.12%	-31.42%	4.54%	0.90
GYREGyre Therapeutics, Inc.	741.77M	7.70	154	-6.78%	6.2%	4.84%		0.02
TVRDTvardi Therapeutics, Inc.	42.31M	4.51	-0.10	-65.96%	-317.54%	-63.46%
UNCYUnicycive Therapeutics, Inc.	134.75M	6.27	-1.12	-100%		-89.15%		0.10
GLTOGalecto, Inc.	38.32M	23.95	-1.29			-237.68%		0.00
IVAInventiva S.A.	1.17B	6.12	-1.73	-47.37%	-13.75%
AKBAAkebia Therapeutics, Inc.	355.59M	1.34	-4.06	-17.7%	-7.07%	-38.24%

Profit & Loss

	Apr 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	49.29K	0	0	0	0	0	0	0	0	0
Revenue Growth %	0%	-1%	-	-	-	-	-	-	-	-
Cost of Goods Sold+	9.73K	18.95K	13.62K	9.02K	0	114.75K	0	0	0	0
COGS % of Revenue	0.2%	-	-	-	-	-	-	-	-	-
Gross Profit+	39.56K	-18.95K	-13.62K	-9.02K	0	-114.75K	0	0	0	0
Gross Margin %	0.8%	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-0.2%	-1.48%	0.28%	0.34%	1%	-	1%	-	-	-
Operating Expenses+	13.83M	52.65M	9.21M	6.89M	8.56M	9.75M	32.73M	11.05M	8.23M	19.49M
OpEx % of Revenue	280.63%	-	-	-	-	-	-	-	-	-
Selling, General & Admin	7.17M	6.25M	5.68M	5.65M	5.08M	5.19M	7.58M	5.68M	5M	6.79M
SG&A % of Revenue	145.49%	-	-	-	-	-	-	-	-	-
Research & Development	6.66M	35.14M	3.53M	1.24M	3.47M	4.56M	25.15M	5.38M	3.23M	12.71M
R&D % of Revenue	135.14%	-	-	-	-	-	-	-	-	-
Other Operating Expenses	-9.68M	33.27M	0	0	0	0	0	0	0	0
Operating Income+	-15.64M	-52.65M	-9.21M	-6.89M	-8.56M	-9.87M	-32.73M	-11.05M	-8.23M	-19.49M
Operating Margin %	-317.3%	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-0.14%	-2.37%	0.83%	0.25%	-0.24%	-0.15%	-2.32%	0.66%	0.26%	-1.37%
EBITDA+	-15.59M	-52.63M	-9.19M	-6.88M	-8.55M	-9.75M	-32.62M	-10.94M	-8.23M	-17.58M
EBITDA Margin %	-316.35%	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-0.15%	-2.38%	0.83%	0.25%	-0.24%	-0.14%	-2.34%	0.66%	0.25%	-1.14%
D&A (Non-Cash Add-back)	46.84K	18.95K	13.62K	9.02K	5.02K	114.75K	108.98K	113.33K	8K	0
EBIT	-15.64M	-51.89M	-9.21M	-6.89M	-8.56M	-9.85M	-32.47M	-11.04M	-7.69M	-17.58M
Net Interest Income+	0	0	0	0	144K	29.37K	-949	-4.44K	-23.97K	1.89M
Interest Income	0	0	0	0	144K	31K	0	0	0	1.91M
Interest Expense	49.08K	32.5M	0	0	0	1.63K	949	4.44K	23.97K	23K
Other Income/Expense	536.3K	764.74K	366.22K	79.83K	160.9K	16.54K	253.88K	4.75K	523K	1.89M
Pretax Income+	-15.1M	-51.89M	-8.84M	-6.81M	-8.39M	-9.85M	-32.47M	-11.05M	-7.71M	-17.6M
Pretax Margin %	-306.41%	-	-	-	-	-	-	-	-	-
Income Tax+	0	-7.96M	0	0	0	0	0	0	0	0
Effective Tax Rate %	0.93%	0.85%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-14.08M	-43.92M	-8.84M	-6.81M	-8.39M	-9.85M	-32.47M	-11.05M	-7.71M	-17.6M
Net Margin %	-285.72%	-	-	-	-	-	-	-	-	-
Net Income Growth %	0%	-2.12%	0.8%	0.23%	-0.23%	-0.17%	-2.3%	0.66%	0.3%	-1.28%
Net Income (Continuing)	-15.1M	-43.92M	-8.84M	-6.81M	-8.39M	-9.85M	-32.47M	-11.05M	-7.71M	-17.6M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-200.61	-624.82	-10022.32	-7359.14	-26.60	-2125.38	-2524.80	-600.80	-31.04	-1.15
EPS Growth %	0.99%	-2.11%	-15.04%	0.27%	1%	-78.9%	-0.19%	0.76%	0.95%	0.96%
EPS (Basic)	-200.61	-624.82	-10022.32	-7359.14	-26.60	-2125.38	-2524.80	-600.80	-31.09	-1.15
Diluted Shares Outstanding	70.19K	879	1.41M	915	3.87K	4.63K	12.86K	18.39K	248.45K	15.27M
Basic Shares Outstanding	70.19K	879	1.41M	915	3.87K	4.63K	12.86K	18.39K	248K	15.27M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Apr 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	20.56M	13.63M	8.06M	13.32M	6.18M	6.8M	5.69M	3.21M	11.68M	96.69M
Cash & Short-Term Investments	20.19M	13.28M	7.73M	12.86M	5.4M	6.71M	5.58M	2.12M	9.79M	94.85M
Cash Only	3.66M	10M	1.6M	12.37M	4.91M	6.25M	5.58M	2.12M	9.79M	94.85M
Short-Term Investments	16.53M	3.28M	6.12M	494.63K	493.88K	462.69K	0	0	0	0
Accounts Receivable	49.45K	72.6K	50.17K	0	0	0	0	0	0	0
Days Sales Outstanding	366.2	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	0	0	0	345.86K	251.58K	64K
Total Non-Current Assets+	52.43M	9.71M	1.83M	16.96K	184.44K	73.19K	303.24K	196.24K	1.12K	0
Property, Plant & Equipment	35.79K	19.11K	9.95K	8.53K	176.01K	64.75K	294.8K	186.69K	0	0
Fixed Asset Turnover	1.38x	-	-	-	-	-	-	-	-	-
Goodwill	11.27M	0	0	0	0	0	0	0	0	0
Intangible Assets	22M	0	0	0	0	0	0	0	0	0
Long-Term Investments	18.02M	8.59M	1.81M	0	0	0	0	0	0	0
Other Non-Current Assets	1.11M	1.11M	8.44K	8.44K	8.44K	8.44K	8.44K	9.55K	1.12K	0
Total Assets+	72.99M	23.34M	9.89M	13.34M	6.37M	6.87M	5.99M	3.4M	11.68M	96.69M
Asset Turnover	0.00x	-	-	-	-	-	-	-	-	-
Asset Growth %	-0.15%	-0.68%	-0.58%	0.35%	-0.52%	0.08%	-0.13%	-0.43%	2.43%	7.27%
Total Current Liabilities+	4.6M	6.2M	1.01M	1.57M	2.53M	2.12M	1.56M	1.85M	3.59M	4.69M
Accounts Payable	972.48K	727.6K	611.86K	749.81K	1.66M	757.86K	859.64K	448.43K	2.07M	3.16M
Days Payables Outstanding	36.49K	14.01K	16.4K	30.36K	-	2.41K	-	-	-	-
Short-Term Debt	0	0	0	0	0	120.49K	0	624.3K	500.9K	0
Deferred Revenue (Current)	1000K	0	0	0	0	0	0	0	0	0
Other Current Liabilities	524.34K	226.09K	33.67K	244.46K	426.12K	319.61K	0	245.39K	236.88K	0
Current Ratio	4.47x	2.20x	7.99x	8.51x	2.44x	3.21x	3.64x	1.74x	3.26x	20.60x
Quick Ratio	4.47x	2.20x	7.99x	8.51x	2.44x	3.21x	3.64x	1.74x	3.26x	20.60x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	7.96M	0	0	0	60.38K	124.17K	183.59K	64.2K	0	0
Long-Term Debt	0	0	0	0	0	124.17K	0	0	0	0
Capital Lease Obligations	0	0	0	0	60.38K	0	183.59K	64.2K	0	0
Deferred Tax Liabilities	7.96M	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0	0	0
Total Liabilities	12.56M	6.2M	1.01M	1.57M	2.59M	2.24M	1.75M	1.91M	3.59M	4.69M
Total Debt+	100.16K	0	0	0	171.73K	305.04K	290.78K	807.89K	500.9K	0
Net Debt	-3.56M	-10M	-1.6M	-12.37M	-4.73M	-5.95M	-5.29M	-1.32M	-9.29M	-94.85M
Debt / Equity	0.00x	-	-	-	0.05x	0.07x	0.07x	0.54x	0.06x	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-318.62x	-1.62x	-	-	-	-6065.11x	-34487.08x	-2487.65x	-343.56x	-847.57x
Total Equity+	60.42M	17.14M	8.88M	11.77M	3.77M	4.63M	4.24M	1.49M	8.1M	91.99M
Equity Growth %	-0.2%	-0.72%	-0.48%	0.33%	-0.68%	0.23%	-0.08%	-0.65%	4.42%	10.36%
Book Value per Share	860.81	19506.16	6.30	12865.06	974.30	997.96	330.07	81.17	32.59	6.02
Total Shareholders' Equity	60.42M	17.14M	8.88M	11.77M	3.77M	4.63M	4.24M	1.49M	8.1M	91.99M
Common Stock	2.81K	2.81K	141	379	674	1.26K	2.52K	4.58K	30	0
Retained Earnings	-160.74M	-204.66M	-213.5M	-227.8M	-236.17M	-246.02M	-278.49M	-289.54M	-297.25M	-314.86M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-129.44K	-18.72K	-16.19K	516	458	-70	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Apr 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-9.75M	-15.87M	-12.14M	-5.5M	-7.56M	-9.27M	-10.86M	-12.01M	-5.9M	-14.81M
Operating CF Margin %	-197.8%	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-0.05%	-0.63%	0.24%	0.55%	-0.37%	-0.23%	-0.17%	-0.11%	0.51%	-1.51%
Net Income	-14.08M	-43.92M	-8.84M	-14.14M	-8.39M	-9.85M	-32.47M	-11.05M	-7.71M	-17.6M
Depreciation & Amortization	148.14K	18.95K	13.62K	9.02K	107.28K	114.75K	108.98K	113.33K	8K	0
Stock-Based Compensation	975	1.06K	79.59K	190.08K	0	0	0	0	191K	1.13M
Deferred Taxes	1.7M	-7.96M	-4.83K	407.77K	0	0	0	0	0	0
Other Non-Cash Items	433.08K	34.08M	498.49K	7.43M	270.51K	361.34K	22.12M	366.86K	25K	23K
Working Capital Changes	1.93M	1.92M	-3.89M	606.75K	460.4K	102.44K	-610.09K	-1.45M	1.58M	1.64M
Change in Receivables	-793.15K	23.8K	1.11M	-122.61K	0	698.37K	-22.5K	0	-306K	58K
Change in Inventory	-2.72M	-2.72M	5M	-729.36K	0	0	0	0	0	0
Change in Payables	2.72M	2.72M	-5M	729.36K	883.04K	0	0	-344.95K	1.65M	1.06M
Cash from Investing+	-40.93M	22.21M	3.75M	7.35M	-1.65K	20.11K	452.61K	-2.32K	3K	0
Capital Expenditures	-109.66K	-2.88K	-4.54K	-7.59K	-3.57K	-3.49K	-5.25K	-2.32K	0	0
CapEx % of Revenue	2.22%	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-98.92K	75K	3.75K	7.36K	0	0	0	0	3K	0
Cash from Financing+	280.59K	280.59K	498.49K	8.91M	96.5K	10.6M	9.74M	8.55M	13.57M	99.87M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	-7.33M	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	280.59K	-489.32K	-498.49K	16.24M	0	1.69M	544.65K	0	14.19M	100.37M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-9.86M	-15.87M	-12.15M	-5.51M	-7.56M	-9.28M	-10.86M	-12.02M	-5.9M	-14.81M
FCF Margin %	-200.03%	-	-	-	-	-	-	-	-	-
FCF Growth %	-0.05%	-0.61%	0.23%	0.55%	-0.37%	-0.23%	-0.17%	-0.11%	0.51%	-1.51%
FCF per Share	-140.45	-18064.61	-8.61	-6018.64	-1952.41	-2001.37	-844.59	-653.32	-23.76	-0.97
FCF Conversion (FCF/Net Income)	0.69x	0.36x	1.37x	0.81x	0.90x	0.94x	0.33x	1.09x	0.77x	0.84x
Interest Paid	0	0	0	0	0	0	0	0	24K	23K
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-20.74%	-113.26%	-67.94%	-65.98%	-108.01%	-234.61%	-732.21%	-385.12%	-160.8%	-35.17%
Return on Invested Capital (ROIC)	-19.15%	-123.38%	-95.75%	-154.76%	-	-	-	-	-	-
Gross Margin	80.26%	-	-	-	-	-	-	-	-	-
Net Margin	-28571.63%	-	-	-	-	-	-	-	-	-
Debt / Equity	0.00x	-	-	-	0.05x	0.07x	0.07x	0.54x	0.06x	-
Interest Coverage	-318.62x	-1.62x	-	-	-	-6065.11x	-34487.08x	-2487.65x	-343.56x	-847.57x
FCF Conversion	0.69x	0.36x	1.37x	0.81x	0.90x	0.94x	0.33x	1.09x	0.77x	0.84x
Revenue Growth	0%	-100%	-	-	-	-	-	-	-	-

Revenue by Segment

	2013
United States	46.02K
United States Growth	-

Revenue by Geography

	2013
Europe	46.67K
Europe Growth	-
United States	46.02K
United States Growth	-

Frequently Asked Questions

Growth & Financials

Tenax Therapeutics, Inc. (TENX) grew revenue by 0.0% over the past year. Growth has been modest.

Tenax Therapeutics, Inc. (TENX) reported a net loss of $43.3M for fiscal year 2024.

Dividend & Returns

Tenax Therapeutics, Inc. (TENX) has a return on equity (ROE) of -35.2%. Negative ROE indicates the company is unprofitable.

Tenax Therapeutics, Inc. (TENX) had negative free cash flow of $25.9M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Tenax Therapeutics, Inc. (TENX) 10-Year Financial Performance & Capital Metrics

TENX • • Industrial / General

HealthcareBiotechnologyMetabolic & Liver DiseasesNASH & Liver Diseases

Revenue $0
EBITDA -$18M -113.7%
Net Income -$18M -128.3%
EPS (Diluted) -1.15 +96.3%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -35.17% +78.1%
ROIC -
Debt/Equity -
Interest Coverage -847.57 -146.7%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 96 (top 4%)

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Shares diluted 100.0% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-197.57%

EPS CAGR

10Y-

5Y-

3Y-

TTM92.92%

ROCE

10Y Avg-191.29%

5Y Avg-304.4%

3Y Avg-192.95%

Latest-38.95%

Peer Comparison

NASH & Liver Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
MAZEMaze Therapeutics, Inc.	1.92B	39.81	511.70		31.18%	-33.24%	3.91%	0.14
GNFTGenfit S.A.	313.52M	6.27	209	134.56%	-14.12%	-31.42%	4.54%	0.90
GYREGyre Therapeutics, Inc.	741.77M	7.70	154	-6.78%	6.2%	4.84%		0.02
TVRDTvardi Therapeutics, Inc.	42.31M	4.51	-0.10	-65.96%	-317.54%	-63.46%
UNCYUnicycive Therapeutics, Inc.	134.75M	6.27	-1.12	-100%		-89.15%		0.10
GLTOGalecto, Inc.	38.32M	23.95	-1.29			-237.68%		0.00
IVAInventiva S.A.	1.17B	6.12	-1.73	-47.37%	-13.75%
AKBAAkebia Therapeutics, Inc.	355.59M	1.34	-4.06	-17.7%	-7.07%	-38.24%

Profit & Loss

	Apr 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	49.29K	0	0	0	0	0	0	0	0	0
Revenue Growth %	0%	-1%	-	-	-	-	-	-	-	-
Cost of Goods Sold+	9.73K	18.95K	13.62K	9.02K	0	114.75K	0	0	0	0
COGS % of Revenue	0.2%	-	-	-	-	-	-	-	-	-
Gross Profit+	39.56K	-18.95K	-13.62K	-9.02K	0	-114.75K	0	0	0	0
Gross Margin %	0.8%	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-0.2%	-1.48%	0.28%	0.34%	1%	-	1%	-	-	-
Operating Expenses+	13.83M	52.65M	9.21M	6.89M	8.56M	9.75M	32.73M	11.05M	8.23M	19.49M
OpEx % of Revenue	280.63%	-	-	-	-	-	-	-	-	-
Selling, General & Admin	7.17M	6.25M	5.68M	5.65M	5.08M	5.19M	7.58M	5.68M	5M	6.79M
SG&A % of Revenue	145.49%	-	-	-	-	-	-	-	-	-
Research & Development	6.66M	35.14M	3.53M	1.24M	3.47M	4.56M	25.15M	5.38M	3.23M	12.71M
R&D % of Revenue	135.14%	-	-	-	-	-	-	-	-	-
Other Operating Expenses	-9.68M	33.27M	0	0	0	0	0	0	0	0
Operating Income+	-15.64M	-52.65M	-9.21M	-6.89M	-8.56M	-9.87M	-32.73M	-11.05M	-8.23M	-19.49M
Operating Margin %	-317.3%	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-0.14%	-2.37%	0.83%	0.25%	-0.24%	-0.15%	-2.32%	0.66%	0.26%	-1.37%
EBITDA+	-15.59M	-52.63M	-9.19M	-6.88M	-8.55M	-9.75M	-32.62M	-10.94M	-8.23M	-17.58M
EBITDA Margin %	-316.35%	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-0.15%	-2.38%	0.83%	0.25%	-0.24%	-0.14%	-2.34%	0.66%	0.25%	-1.14%
D&A (Non-Cash Add-back)	46.84K	18.95K	13.62K	9.02K	5.02K	114.75K	108.98K	113.33K	8K	0
EBIT	-15.64M	-51.89M	-9.21M	-6.89M	-8.56M	-9.85M	-32.47M	-11.04M	-7.69M	-17.58M
Net Interest Income+	0	0	0	0	144K	29.37K	-949	-4.44K	-23.97K	1.89M
Interest Income	0	0	0	0	144K	31K	0	0	0	1.91M
Interest Expense	49.08K	32.5M	0	0	0	1.63K	949	4.44K	23.97K	23K
Other Income/Expense	536.3K	764.74K	366.22K	79.83K	160.9K	16.54K	253.88K	4.75K	523K	1.89M
Pretax Income+	-15.1M	-51.89M	-8.84M	-6.81M	-8.39M	-9.85M	-32.47M	-11.05M	-7.71M	-17.6M
Pretax Margin %	-306.41%	-	-	-	-	-	-	-	-	-
Income Tax+	0	-7.96M	0	0	0	0	0	0	0	0
Effective Tax Rate %	0.93%	0.85%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-14.08M	-43.92M	-8.84M	-6.81M	-8.39M	-9.85M	-32.47M	-11.05M	-7.71M	-17.6M
Net Margin %	-285.72%	-	-	-	-	-	-	-	-	-
Net Income Growth %	0%	-2.12%	0.8%	0.23%	-0.23%	-0.17%	-2.3%	0.66%	0.3%	-1.28%
Net Income (Continuing)	-15.1M	-43.92M	-8.84M	-6.81M	-8.39M	-9.85M	-32.47M	-11.05M	-7.71M	-17.6M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-200.61	-624.82	-10022.32	-7359.14	-26.60	-2125.38	-2524.80	-600.80	-31.04	-1.15
EPS Growth %	0.99%	-2.11%	-15.04%	0.27%	1%	-78.9%	-0.19%	0.76%	0.95%	0.96%
EPS (Basic)	-200.61	-624.82	-10022.32	-7359.14	-26.60	-2125.38	-2524.80	-600.80	-31.09	-1.15
Diluted Shares Outstanding	70.19K	879	1.41M	915	3.87K	4.63K	12.86K	18.39K	248.45K	15.27M
Basic Shares Outstanding	70.19K	879	1.41M	915	3.87K	4.63K	12.86K	18.39K	248K	15.27M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Apr 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	20.56M	13.63M	8.06M	13.32M	6.18M	6.8M	5.69M	3.21M	11.68M	96.69M
Cash & Short-Term Investments	20.19M	13.28M	7.73M	12.86M	5.4M	6.71M	5.58M	2.12M	9.79M	94.85M
Cash Only	3.66M	10M	1.6M	12.37M	4.91M	6.25M	5.58M	2.12M	9.79M	94.85M
Short-Term Investments	16.53M	3.28M	6.12M	494.63K	493.88K	462.69K	0	0	0	0
Accounts Receivable	49.45K	72.6K	50.17K	0	0	0	0	0	0	0
Days Sales Outstanding	366.2	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	0	0	0	345.86K	251.58K	64K
Total Non-Current Assets+	52.43M	9.71M	1.83M	16.96K	184.44K	73.19K	303.24K	196.24K	1.12K	0
Property, Plant & Equipment	35.79K	19.11K	9.95K	8.53K	176.01K	64.75K	294.8K	186.69K	0	0
Fixed Asset Turnover	1.38x	-	-	-	-	-	-	-	-	-
Goodwill	11.27M	0	0	0	0	0	0	0	0	0
Intangible Assets	22M	0	0	0	0	0	0	0	0	0
Long-Term Investments	18.02M	8.59M	1.81M	0	0	0	0	0	0	0
Other Non-Current Assets	1.11M	1.11M	8.44K	8.44K	8.44K	8.44K	8.44K	9.55K	1.12K	0
Total Assets+	72.99M	23.34M	9.89M	13.34M	6.37M	6.87M	5.99M	3.4M	11.68M	96.69M
Asset Turnover	0.00x	-	-	-	-	-	-	-	-	-
Asset Growth %	-0.15%	-0.68%	-0.58%	0.35%	-0.52%	0.08%	-0.13%	-0.43%	2.43%	7.27%
Total Current Liabilities+	4.6M	6.2M	1.01M	1.57M	2.53M	2.12M	1.56M	1.85M	3.59M	4.69M
Accounts Payable	972.48K	727.6K	611.86K	749.81K	1.66M	757.86K	859.64K	448.43K	2.07M	3.16M
Days Payables Outstanding	36.49K	14.01K	16.4K	30.36K	-	2.41K	-	-	-	-
Short-Term Debt	0	0	0	0	0	120.49K	0	624.3K	500.9K	0
Deferred Revenue (Current)	1000K	0	0	0	0	0	0	0	0	0
Other Current Liabilities	524.34K	226.09K	33.67K	244.46K	426.12K	319.61K	0	245.39K	236.88K	0
Current Ratio	4.47x	2.20x	7.99x	8.51x	2.44x	3.21x	3.64x	1.74x	3.26x	20.60x
Quick Ratio	4.47x	2.20x	7.99x	8.51x	2.44x	3.21x	3.64x	1.74x	3.26x	20.60x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	7.96M	0	0	0	60.38K	124.17K	183.59K	64.2K	0	0
Long-Term Debt	0	0	0	0	0	124.17K	0	0	0	0
Capital Lease Obligations	0	0	0	0	60.38K	0	183.59K	64.2K	0	0
Deferred Tax Liabilities	7.96M	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0	0	0
Total Liabilities	12.56M	6.2M	1.01M	1.57M	2.59M	2.24M	1.75M	1.91M	3.59M	4.69M
Total Debt+	100.16K	0	0	0	171.73K	305.04K	290.78K	807.89K	500.9K	0
Net Debt	-3.56M	-10M	-1.6M	-12.37M	-4.73M	-5.95M	-5.29M	-1.32M	-9.29M	-94.85M
Debt / Equity	0.00x	-	-	-	0.05x	0.07x	0.07x	0.54x	0.06x	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-318.62x	-1.62x	-	-	-	-6065.11x	-34487.08x	-2487.65x	-343.56x	-847.57x
Total Equity+	60.42M	17.14M	8.88M	11.77M	3.77M	4.63M	4.24M	1.49M	8.1M	91.99M
Equity Growth %	-0.2%	-0.72%	-0.48%	0.33%	-0.68%	0.23%	-0.08%	-0.65%	4.42%	10.36%
Book Value per Share	860.81	19506.16	6.30	12865.06	974.30	997.96	330.07	81.17	32.59	6.02
Total Shareholders' Equity	60.42M	17.14M	8.88M	11.77M	3.77M	4.63M	4.24M	1.49M	8.1M	91.99M
Common Stock	2.81K	2.81K	141	379	674	1.26K	2.52K	4.58K	30	0
Retained Earnings	-160.74M	-204.66M	-213.5M	-227.8M	-236.17M	-246.02M	-278.49M	-289.54M	-297.25M	-314.86M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-129.44K	-18.72K	-16.19K	516	458	-70	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Apr 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-9.75M	-15.87M	-12.14M	-5.5M	-7.56M	-9.27M	-10.86M	-12.01M	-5.9M	-14.81M
Operating CF Margin %	-197.8%	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-0.05%	-0.63%	0.24%	0.55%	-0.37%	-0.23%	-0.17%	-0.11%	0.51%	-1.51%
Net Income	-14.08M	-43.92M	-8.84M	-14.14M	-8.39M	-9.85M	-32.47M	-11.05M	-7.71M	-17.6M
Depreciation & Amortization	148.14K	18.95K	13.62K	9.02K	107.28K	114.75K	108.98K	113.33K	8K	0
Stock-Based Compensation	975	1.06K	79.59K	190.08K	0	0	0	0	191K	1.13M
Deferred Taxes	1.7M	-7.96M	-4.83K	407.77K	0	0	0	0	0	0
Other Non-Cash Items	433.08K	34.08M	498.49K	7.43M	270.51K	361.34K	22.12M	366.86K	25K	23K
Working Capital Changes	1.93M	1.92M	-3.89M	606.75K	460.4K	102.44K	-610.09K	-1.45M	1.58M	1.64M
Change in Receivables	-793.15K	23.8K	1.11M	-122.61K	0	698.37K	-22.5K	0	-306K	58K
Change in Inventory	-2.72M	-2.72M	5M	-729.36K	0	0	0	0	0	0
Change in Payables	2.72M	2.72M	-5M	729.36K	883.04K	0	0	-344.95K	1.65M	1.06M
Cash from Investing+	-40.93M	22.21M	3.75M	7.35M	-1.65K	20.11K	452.61K	-2.32K	3K	0
Capital Expenditures	-109.66K	-2.88K	-4.54K	-7.59K	-3.57K	-3.49K	-5.25K	-2.32K	0	0
CapEx % of Revenue	2.22%	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-98.92K	75K	3.75K	7.36K	0	0	0	0	3K	0
Cash from Financing+	280.59K	280.59K	498.49K	8.91M	96.5K	10.6M	9.74M	8.55M	13.57M	99.87M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	-7.33M	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	280.59K	-489.32K	-498.49K	16.24M	0	1.69M	544.65K	0	14.19M	100.37M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-9.86M	-15.87M	-12.15M	-5.51M	-7.56M	-9.28M	-10.86M	-12.02M	-5.9M	-14.81M
FCF Margin %	-200.03%	-	-	-	-	-	-	-	-	-
FCF Growth %	-0.05%	-0.61%	0.23%	0.55%	-0.37%	-0.23%	-0.17%	-0.11%	0.51%	-1.51%
FCF per Share	-140.45	-18064.61	-8.61	-6018.64	-1952.41	-2001.37	-844.59	-653.32	-23.76	-0.97
FCF Conversion (FCF/Net Income)	0.69x	0.36x	1.37x	0.81x	0.90x	0.94x	0.33x	1.09x	0.77x	0.84x
Interest Paid	0	0	0	0	0	0	0	0	24K	23K
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-20.74%	-113.26%	-67.94%	-65.98%	-108.01%	-234.61%	-732.21%	-385.12%	-160.8%	-35.17%
Return on Invested Capital (ROIC)	-19.15%	-123.38%	-95.75%	-154.76%	-	-	-	-	-	-
Gross Margin	80.26%	-	-	-	-	-	-	-	-	-
Net Margin	-28571.63%	-	-	-	-	-	-	-	-	-
Debt / Equity	0.00x	-	-	-	0.05x	0.07x	0.07x	0.54x	0.06x	-
Interest Coverage	-318.62x	-1.62x	-	-	-	-6065.11x	-34487.08x	-2487.65x	-343.56x	-847.57x
FCF Conversion	0.69x	0.36x	1.37x	0.81x	0.90x	0.94x	0.33x	1.09x	0.77x	0.84x
Revenue Growth	0%	-100%	-	-	-	-	-	-	-	-

Revenue by Segment

	2013
United States	46.02K
United States Growth	-

Revenue by Geography

	2013
Europe	46.67K
Europe Growth	-
United States	46.02K
United States Growth	-

Frequently Asked Questions

Growth & Financials

Tenax Therapeutics, Inc. (TENX) grew revenue by 0.0% over the past year. Growth has been modest.

Tenax Therapeutics, Inc. (TENX) reported a net loss of $43.3M for fiscal year 2024.

Dividend & Returns

Tenax Therapeutics, Inc. (TENX) has a return on equity (ROE) of -35.2%. Negative ROE indicates the company is unprofitable.

Tenax Therapeutics, Inc. (TENX) had negative free cash flow of $25.9M in fiscal year 2024, likely due to heavy capital investments.